BN Business News
Add your company to Business Communicator →

Regulation & law · 18/12/2015

National Cancer Institute to Grant Exclusive Patent License to Heliome Biotech for Farnesoid X Receptor Inhibitor

The National Cancer Institute is considering granting an exclusive patent license to Heliome Biotech, Inc. to develop a small molecule farnesoid X receptor inhibitor, as outlined in U.S. patents and patent applications.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights